1 / 27

Aplicable Disease

Aplicable Disease. World Health Organization 1997. Atherosclerosis and its consequences (ASPVD, ASCAD, ASCVD) and Cancer together are responsible for over 80% of ALL deaths in industrialized countries. “Cardiovascular Drug Therapy”1996. Metal Toxicity & Heart Disease.

nadine
Télécharger la présentation

Aplicable Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Aplicable Disease

  2. World Health Organization 1997 • Atherosclerosis and its consequences (ASPVD, ASCAD, ASCVD) and Cancer together are responsible for over 80% of ALL deaths in industrialized countries

  3. “Cardiovascular Drug Therapy”1996

  4. Metal Toxicity & Heart Disease • Chapter 175 MagnesiumEDTA chelation Martin Rubin PhD • EDTA acts as an anti-oxidant, anti-coagulant and decalcifies deposits. • 30 infusions of EDTA in a patient 14 years post MI and multi-vessel CABG. Ultrafast CT scan showed 216 calcified lesions and total calcium score of 15872. Post chelation: 118 lesions, calcium score 7970 Martin Rubin PhD

  5. Metal Toxicity & Heart Disease • “EDTA chelation has an implicit advantage in that it can favorably influence all facets of the (atherosclerotic) disease development. Thus it can also provide an alternative to the combination of drugs administered to obtain a multiplicity of therapeutic effects.” Prof. Martin Rubin

  6. Metal Toxicity & Heart Disease

  7. Metal Toxicity & Heart Disease Idiopathic Dilated Cardiomyopathy • Hg – 22,000 x normal • Sb – 12,000 x normal • Au – 11 x normal • Cr – 13 x normal • Co – 4 x normal Journal of American College of Cardiology, 1999

  8. Metal Toxicity & PVD

  9. Metal Toxicity & PVD • 79 year old woman - Presenting History • 1979 NIDDM and hypertension • 1992 Mastectomy for breast carcinoma • 1993 Increasing PVD • 1996 Left hemiplegia CVA • 1997 March - Severe pain in left foot at rest. Hospitalized but refused angiogram and possible amputation. Started chelation. Medications: Minidiab, Adalat, Quinine sulphate, Warfarin

  10. Became pain-free with improved circulation after 6 weeks of chelation. • Discharged from the hospital vascular clinic after 6 months. • Maintained on monthly chelations for 4 years

  11. Metal Toxicity & PVD • 3 blinded controlled trials • Olszewer and Carter—10 patients crossover • Van Rij—32 patients, slight improvement, one major outlier • Guldagger—51% vs. 24% improved • Underpowered, 1/3 dropout • Statistical problems • Patients continued to smoke • Did not follow the standard protocol as claimed

  12. Metal Toxicity & Vascular Disease Multi-Centered Trial • 220 patients with documented vascular disease • Received chelation with three year follow-up • No deaths or MIs, 4 minor strokes • Symptoms improved • Chappell, Mitchell, Born, Ventresco, Hancke, Olszewer, van der Schaar, Blaha

  13. Metal Toxicity & Vascular Disease Multi-Centered Trial • Compared to conventional therapies • Expected 31/220 angioplasties, we had 2 • Expected 16/220 CABG, we had 6 • Expected 15/220 MI’s, we had none • Expected 6/220 deaths, we had none • Of 185 patients with symptoms, 68% had a complete resolution

  14. Metal Toxicity & MI • Improved myocardial perfusion in patients with advanced ischemic heart disease with an integrative management program including EDTA metal binding therapy. Ali M, et al. J Integrative Med.1997;1:7-112

  15. Metal Toxicity & MI • Comparative study of pre- and post-chelation myocardial thallium perfusion scans showed clear, objective evidence of significant improvement in myocardial perfusion in five of six patients in whom such studies were performed

  16. Metal Toxicity & Heart Disease • EDTA Chelation Therapy in Myocardial Stunning and Hibernation. Edwards D, et al. J.Adv.Med 1997;10,4:233-257 • 5 Case Reports • All patients were studied using first-pass radionuclide ventriculography (RNV) All ejection fractions improved

  17. Metal Toxicity & Heart Disease • Conclusion: EDTA Metal Binding Therapy clearly and convincingly reverses the condition of myocardial hibernation and possibly stunning

  18. Metal Toxicity & ANGINA • Kitchell and Meltzer-- small controlled trial, and 71% of 38 patients with disabling angina improved symptoms and exercise capacity • Hancke and Flytlie—69% of 253 patients improved EKG and exercise capacity, 91% of 207 patients on NTG stopped it, 58/65 on waiting list for Bypass avoided surgery

  19. Metal Toxicity & ANGINA • Casdorph 16/18 improved ejection fractions • Clarke 16/20 patients assymptomatic after chelation • Olszewer and Carter 844 patients, 77% marked improvement, 16% good improvement

  20. Metal Toxicity & Autism Important Issues of: • Blood Brain Barrier • Protein Structure • Total Mercury Reservoir

  21. Metal Toxicity & Autism Retrospective Study • 31 patients with diagnosis: • Autism • Autism Like Spectrum • Pervasive Developmental Delay

  22. Metal Toxicity & Autism Key To Success - Protocol • Trans Dermal DMPS (TD-DMPS) • 4 : 1 Ratio of GSH : DMPS • Conjugated with amino acids, • Delivered in a micro-encapsulated liposomal phospholipid base

  23. Metal Toxicity & Autism Retrospective Study • Baseline • 2 months • 4 months • 6 months • 8 months • 10 months • 12 months • then 4 months

  24. Metal Toxicity & Autism Retrospective Study • All 31 patients tested: • Urine Metal Toxicity & Essentials • Hair Metal Toxicity & Essentials • RBC Metal Toxicity • Fecal Metal Toxicity

  25. Metal Toxicity & Autism Retrospective Study • All 31 patients showed LITTLE or NO level of mercury on initial baseline test results

More Related